Allogene Therapeutics (ALLO) Current Assets (2018 - 2026)

Allogene Therapeutics has reported Current Assets for 9 years, with the latest figure at $273.3 million in Q1 2026.

• Quarterly Current Assets fell 6.27% year-over-year to $273.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.3 million (down 6.27% YoY) and the FY2025 annual result came in at $257.7 million, down 15.04% from the prior year.
• Current Assets advanced to $273.3 million in Q1 2026 per ALLO's latest filing, from $257.7 million in the prior quarter.
• Over five years, Current Assets peaked at $569.1 million in Q3 2022 and troughed at $257.7 million in Q4 2025.
• A 5-year average of $401.4 million and a median of $457.1 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets grew 13.17% in 2022, then sank 38.17% in 2025.
• Over 5 years, Current Assets stood at $528.8 million in 2022, then dropped by 13.18% to $459.1 million in 2023, then tumbled by 33.92% to $303.4 million in 2024, then declined by 15.04% to $257.7 million in 2025, then climbed by 6.03% to $273.3 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $273.3 million, $257.7 million, and $260.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.